Compare BHVN & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHVN | STOK |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2022 | 2019 |
| Metric | BHVN | STOK |
|---|---|---|
| Price | $15.44 | $29.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | $29.08 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 3.6M | 1.0M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.08 | ★ 92.73 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $77.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $7.48 | $12.25 |
| 52 Week High | $18.57 | $40.22 |
| Indicator | BHVN | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 57.56 | 38.38 |
| Support Level | $14.44 | $28.22 |
| Resistance Level | $17.01 | $33.51 |
| Average True Range (ATR) | 1.01 | 1.56 |
| MACD | -0.28 | -0.38 |
| Stochastic Oscillator | 49.72 | 12.29 |
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.